$CUE News

Cue: The Market Is Paying $86M For A Drug It Doesn't Own

Cue Biopharma Announces Board Transition and Addition of New Directors with Continued Company Evolution

Cue Biopharma to Present at the 2026 Jefferies Global Healthcare Conference

Cue Biopharma Reports First Quarter 2026 Financial Results and Recent Strategic Developments

Cue Biopharma Q1 EPS $(1.08) Misses $(0.10) Estimate, Sales $5.686M Beat $1.875M Estimate

Watching Cue Biopharma; Fugazi Research Issues Report On Co. Titled "$CUE: Reverse Splits, PIPE Dilution, and the Illusion of Recovery"

Cue Biopharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Cue Biopharma Stock Surges Over 65% Overnight: Why Is It Moving?

Cue Biopharma Announces $30 Million Private Placement

Cue Biopharma Expands Pipeline with Exclusive License from Ascendant Health Sciences Ltd. for Clinical-Stage Dual-Mechanism Anti-IgE Antibody

Cue Biopharma Names Shao-Lee Lin M.D., Ph.D., CEO, President and Board Director to Lead Continued Growth and Transformation into a Clinical-Stage Company

Cue Biopharma Announces Private Placement For Gross Proceeds Of ~$30M, Selling Pre‑Funded Warrants For Up To 2.7M Shares And Accompanying $11 Warrants For 1.36M Shares

Cue Biopharma Enters Into Exclusive License Agreement With Ascendant Health To Develop, Manufacture And Commercialize Ascendant-221, Phase 2 Clinical Stage Anti-IgE Monoclonal Antibody For Treatment Of Allergic Diseases

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

Cue Biopharma Announces 1-for-30 Reverse Stock Split

What's Behind The Drop In Cue Biopharma Stock Today?

Cue Biopharma shares are trading lower after the company announced a 1-for-30 reverse stock split.

Cue Biopharma Announces 1-For-30 Reverse Stock Split Effective After Market Close On April 23

Cue Biopharma shares are trading higher. The company announced it will present new preclinical data for its lead autoimmune and inflammatory disease candidate, CUE-401, at IMMUNOLOGY2026.